Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

The recent emergence of B. 1.1. 529, the Omicron variant,, has raised concerns of escape
from protection by vaccines and therapeutic antibodies. A key test for potential …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …

Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with
antigenic changes in the spike protein are neutralized less efficiently by serum antibodies …

SARS-CoV-2 has been spreading around the world for the past year. Recently, several
variants such as B. 1.1. 7 (alpha), B. 1.351 (beta), and P. 1 (gamma), which share a key …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …